FDA allows Wegov weight to reduce heart attacks

The US health authorities said on Friday that the ‘wigofi’ means, previously allowed to use in the United States to lose weight, were also approved to reduce the risk of obesity or excessive weight with cardiovascular disease or heart attacks. “Weevi is now the first remedy that loses weight, also authorized to help prevent cardiovascular injuries that can be deadly, in these patients who are overweight,” says John Sharetz, head of the US Food and Drug Administration. About 70% of American adults suffer from obesity or weight gain, according to the food and drug administration, which emphasized that the use of ‘wigofi’ is accompanied by low -calorie diet with increased physical activity. The decision of the administration was based on a wide clinical trial; During which 17 thousand and 600 people either “Novo Nordisk” or another false were received. The US authority emphasized that “wigofi” significantly reduced the number of heart attacks and blood vessels, such as heart attacks or strokes, as these diseases struck 6.5% of participants who received “Wigofi” compared to 8% of participants who received a false medicine. What is the “Wigofi” medicine? Wigofi belongs to a new generation of drugs that simulate the hormone of the GLP-1, which quickly became one of the best-selling medicine around the world. In 2021, the US authorities authorized the use of ‘wigofi’ on the basis of the ‘simaglotide’ who are partially part for individuals suffering from obesity or weight gain, as well as a health problem associated with it, such as type 2 diabetes, cholesterol and others. It is given by injection ‘wigofi’, and it can cause serious side effects such as pancreatitis, and it can cause nausea, diarrhea, vomiting, constipation and others. Recently, a periodic shortage of the quantities is available at the “Osmbek” medicine for diabetes and licensed in the United States since 2017, and Osmbek “as” and “Wi -Fofi” is on Simajlotide. The decision can expand the extent of the coverage of health insurance companies for the purchase of this medicine produced by the “Novo Nordsk” group, as a large part of it does not lose the medicine prescribed only to lose weight, but the high prices of this medicine prevent it from buying it. “Novo Nordisk” shares the US “Eli Lily” group, the high -profit market for anti -pharmacy medicine.